[ORGANIZATION]
Moderna Inc.
Featured in 8 tracked stories · first seen
Situations
Moderna and Merck melanoma vaccine clinical trials
9 clusters · 443 sources · last updated
Latest: Moderna reports positive Phase III results for personalized cancer vaccine
Moderna and Merck (MSD) have reported positive Phase 3 clinical trial results for intismeran autogene (also known as V940 or mRNA-4157), an experimental personalized mRNA cancer vaccine. The therapy is designed to target
US stock market valuation and fiscal deficit concerns
12 clusters · 198 sources · last updated
Latest: S&P 500 faces high valuations amid historical September market weakness
In mid-August 2026, the S&P 500 reached new milestones, surpassing 7,800 points intraday before closing at 7,798.99. This surge was supported by the energy sector, healthcare, and financial services, alongside robust cor
Bundibugyo Ebola vaccine trials
4 clusters · 58 sources · last updated
Latest: Minapharm Group receives $16.5M for Bundibugyo ebola vaccine
Clinical efforts to address the Bundibugyo Ebola outbreak in the Democratic Republic of the Congo (DRC) continue to expand. The outbreak, which has seen infections surpass 4,000 cases, has prompted the WHO and Africa CDC
BioNTech restructuring, oncology shift, revenue cut
11 clusters · 42 sources · last updated
Latest: BioNTech halts personalized mRNA colorectal cancer vaccine trial
In August 2026, BioNTech significantly reduced its full-year revenue outlook to €1.6–1.9 billion, down from a previous target of €2.0–2.3 billion, citing declining COVID-19 vaccine demand and lost milestone payments. The
Moderna mRNA flu vaccine US approval
4 clusters · 68 sources · last updated
Latest: Moderna's mFLUSIVA receives FDA approval as first mRNA flu vaccine
In early August 2026, the U.S. Food and Drug Administration (FDA) authorized Moderna’s mRNA-based seasonal influenza vaccine, mFlusiva. On 6 August, the agency granted full approval for adults aged 50–64, based on a late